BioCardia, Inc. (NASDAQ:BCDA – Get Free Report) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 1,010,000 shares, a growth of 927.5% from the February 29th total of 98,300 shares. Based on an average daily trading volume, of 378,600 shares, the days-to-cover ratio […]
BioCardia, Inc. (NASDAQ:BCDA – Get Free Report) CEO Peter Altman acquired 108,108 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were acquired at an average cost of $0.46 per share, with a total value of $49,729.68. Following the transaction, the chief executive officer now owns 555,447 shares in […]
BioCardia, Inc. (NASDAQ:BCDA – Get Free Report) major shareholder Phillip Md Et Al Frost sold 129,802 shares of BioCardia stock in a transaction on Friday, January 19th. The stock was sold at an average price of $0.43, for a total transaction of $55,814.86. Following the completion of the transaction, the insider now owns 1,896,025 shares […]
BioCardia, Inc. (NASDAQ:BCDA – Get Free Report) major shareholder Phillip Md Et Al Frost sold 129,802 shares of BioCardia stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $0.43, for a total value of $55,814.86. Following the transaction, the insider now owns 1,896,025 shares of […]
BioCardia (NASDAQ:BCDA – Get Free Report) and Vitro Diagnostics (OTCMKTS:VODG – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership. Earnings and Valuation This table compares BioCardia and Vitro […]
Shares of BioCardia, Inc. (NASDAQ:BCDAW – Get Free Report) rose 74.2% during mid-day trading on Monday . The company traded as high as $0.12 and last traded at $0.12. Approximately 667 shares changed hands during trading, a decline of 82% from the average daily volume of 3,704 shares. The stock had previously closed at $0.07. […]
By Dean Seal Shares of BioCardia more than doubled after the company said regulators have approved a Phase 3 trial of its CardiAMP treatment for patients.